CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development
The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...
Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...
CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials
The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...
Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study
US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...
Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...
Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry
The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...
CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...
SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services
Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...
Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...
BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE
Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...
Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward
US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...
Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D
Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....
Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip
Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...
MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...
Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma
Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...
Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast
US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...
AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research
AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...
GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...
Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...